NEW YORK (GenomeWeb News) – The US Food and Drug Administration today said it has cleared Affymetrix’s CytoScan Dx Assay for marketing in the US.

The assay can detect chromosomal variations that may be responsible for developmental delay or intellectual disability in children. The test analyzes an entire genome at one time and detects large and small chromosomal changes, based on a blood sample, FDA said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.